SOUTH PLAINFIELD, NJ--(Marketwire -06/18/12)- GENEWIZ, Inc., leading global DNA service provider, received Clinical Laboratory Improvement Amendments (CLIA) Licensure and Certificate of Registration from the State of New Jersey.
CLIA certification marks the milestone expansion of GENEWIZ solutions to include clinical genomic testing, thus contributing to advancements in personalized medicine. Beyond the Kras and EGFR tests, GENEWIZ intends to continue development of additional CLIA-certified assays through utilization of both traditional platforms and new cutting edge technologies, such as next generation sequencing.
"With CLIA registration, GENEWIZ now has the capacity to provide comprehensive solutions for clients working in clinical environments," stated Conrad Leung, Vice President, GENEWIZ, Inc. "We are committed to providing clinical researchers, physicians, and patients with genomic testing results that ultimately lead to better diagnoses and more effective treatments."
To support the growth of clinical genomic testing, GENEWIZ recently expanded laboratory operations at their Global Headquarters in South Plainfield, NJ to include a clean suite dedicated to the processing of clinical and pre-clinical samples. This laboratory enables GENEWIZ to provide expanded services in the areas of biologic drug and cell bank characterization testing, clinical trial investigations, and clinical diagnostic testing.
About GENEWIZ, Inc.
GENEWIZ, Inc. is a global contract research organization (CRO) specializing in DNA-based services, including DNA sequencing, gene synthesis, molecular biology, genomic, bioinformatics, and GLP/cGMP regulatory-compliant services. GENEWIZ leads the industry in outsourcing partnerships with pharmaceutical, biotechnology, clinical, academic, and government institutions.
Headquartered in South Plainfield, NJ, GENEWIZ, Inc. is a privately-held global enterprise with locations in Boston, MA; San Diego, CA; Washington, DC Metro; Research Triangle Park, NC; and Seattle, WA. International locations include Beijing, China; Suzhou, China; and London, United Kingdom.